US64049M2098 - Common Stock
NEOGENOMICS INC
NASDAQ:NEO (4/25/2024, 2:36:52 PM)
13.98
-0.05 (-0.36%)
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,100 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913
P: 12397680600
CEO: Douglas M. VanOort
Employees: 2100
Website: https://neogenomics.com/
Here you can normally see the latest stock twits on NEO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: